BACKGROUND: The Czech Breast Cancer Screening Programme (CBCSP) was initiated in September 2002 by establishing a network of accredited centres. The aim of this article is to describe progress in the programme quality over time after the inception of the organised programme. METHODS: The CBCSP is monitored using an information system consisting of three principal components: 1) the national cancer registry, 2) a screening registry collecting data on all screening examinations, further assessments and final diagnoses at accredited programme centres, and 3) administrative databases of healthcare payers. Key performance indicators from the European Guidelines have been adopted for continuous monitoring. RESULTS: Breast cancer incidence in the Czech Republic has steadily been increasing, however with a growing proportion of less advanced stages. The mortality rate has recently stabilised. The screening registry includes 2,083,285 records on screening episodes between 2002 and 2008. In 2007-2008, 51% of eligible women aged 45-69 were screened. In 2008, the detection rates were 6.1 and 3.7 per 1,000 women in initial and subsequent screening respectively. Corresponding recall rates are 3.9% and 2.2%, however, it is necessary to pay attention to further assessment performed during the screening visits. Benign to malignant open biopsy ratio was 0.1. Of invasive cases detected in screening, 35.6% was less than 10 mm in diameter. Values of early performance indicators, as measured by both crude and standardized estimates, are generally improving and fulfil desirable targets set by European Guidelines. CONCLUSIONS: Mammography screening in the Czech Republic underwent successful transformation from opportunistic prevention to an organised programme. Values of early indicators confirm continuous improvement in different aspects of process quality. Further stimulation of participation through invitation system is necessary to exploit the full potential of screening mammography at the population level.

Institute of Biostatistics and Analyses Masaryk University Kamenice 126 3 625 00 Brno Czech Republic

Zobrazit více v PubMed

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. doi: 10.3322/canjclin.55.2.74. PubMed DOI

Dusek L, Czech Cancer Care in Numbers 2008-2009. Praha: Grada Publishing, a.s; 2009.

Zatonski W, Didkowska J. Closing the gap: cancer in Central and Eastern Europe (CEE) Eur J Cancer. 2008;44:1425–1437. doi: 10.1016/j.ejca.2008.02.014. PubMed DOI

Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, Andersson I, Bjurstam N, Fagerberg G, Frisell J. et al.Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet. 1993;341:973–978. doi: 10.1016/0140-6736(93)91067-V. PubMed DOI

Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2009. p. CD001877. PubMed

Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:727–737. W237-742. PubMed PMC

Shapiro S, Coleman EA, Broeders M, Codd M, de Koning H, Fracheboud J, Moss S, Paci E, Stachenko S, Ballard-Barbash R. Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European Network of Pilot Projects for Breast Cancer Screening. Int J Epidemiol. 1998;27:735–742. doi: 10.1093/ije/27.5.735. PubMed DOI

Karsa L, Anttila A, Ronco G, Ponti A, Malila N, Arbyn M, Segnan N, Castillo-Beltran M, Boniol M, Ferlay J, Cancer Screening in the European Union: Report on the implementation of the Council Recommendation on cancer screening. Luxembourg: European Communities; 2008.

Schopper D, de Wolf C. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer. 2009;45:1916–1923. doi: 10.1016/j.ejca.2009.03.022. PubMed DOI

U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716–726. W-236. PubMed

Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L, Puthaar E, (Eds) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th ed. Luxembourg: Office for Official Publications of the EC; 2006. PubMed

Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. Ann Oncol. 2008;19:614–622. PubMed

Vainio H, Bianchini F. Breast Cancer Screening. Lyon: IARCPress; 2002.

Day NE, Williams DR, Khaw KT. Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer. 1989;59:954–958. doi: 10.1038/bjc.1989.203. PubMed DOI PMC

Hertl K, Primic-Zakelj M, Zgajnar J, Kocijancic I. Performance of opportunistic breast cancer screening in Slovenia. Neoplasma. 2006;53:237–241. PubMed

Boncz I, Sebestyen A, Dobrossy L, Pentek Z, Budai A, Kovacs A, Dozsa C, Ember I. The organisation and results of first screening round of the Hungarian nationwide organised breast cancer screening programme. Ann Oncol. 2007;18:795–799. PubMed

Boncz I, Sebestyen A, Pinter I, Battyany I, Ember I. The effect of an organized, nationwide breast cancer screening programme on non-organized mammography activities. J Med Screen. 2008;15:14–17. doi: 10.1258/jms.2008.007070. PubMed DOI

American College of Radiology. Illustrated breast imaging reporting and data system. Reston, VA: American College of Radiology; 1998.

Gram IT, Funkhouser E, Tabar L. The Tabar classification of mammographic parenchymal patterns. Eur J Radiol. 1997;24:131–136. doi: 10.1016/S0720-048X(96)01138-2. PubMed DOI

Epidemiology of Malignant Tumours in the Czech Republic. http://www.svod.cz/

Jensen O, Parkin DM, MacLennan R, Muir C, Skeet R. Cancer Registration: Principles and Methods. Lyon: International Agency for Research on Cancer; 1991.

Kan L, Olivotto IA, Warren Burhenne LJ, Sickles EA, Coldman AJ. Standardized abnormal interpretation and cancer detection ratios to assess reading volume and reader performance in a breast screening program. Radiology. 2000;215:563–567. PubMed

StataCorp. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP; 2007.

Sarkeala T, Heinavaara S, Anttila A. Organised mammography screening reduces breast cancer mortality: a cohort study from Finland. Int J Cancer. 2008;122:614–619. doi: 10.1002/ijc.23070. PubMed DOI

Gabe R, Tryggvadottir L, Sigfusson BF, Olafsdottir GH, Sigurdsson K, Duffy SW. A case-control study to estimate the impact of the Icelandic population-based mammography screening program on breast cancer death. Acta Radiol. 2007;48:948–955. doi: 10.1080/02841850701501725. PubMed DOI

Otto SJ, Fracheboud J, Looman CW, Broeders MJ, Boer R, Hendriks JH, Verbeek AL, de Koning HJ. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet. 2003;361:1411–1417. doi: 10.1016/S0140-6736(03)13132-7. PubMed DOI

Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ. 2000;321:665–669. doi: 10.1136/bmj.321.7262.665. PubMed DOI PMC

Olsen AH, Njor SH, Vejborg I, Schwartz W, Dalgaard P, Jensen MB, Tange UB, Blichert-Toft M, Rank F, Mouridsen H, Lynge E. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ. 2005;330:220. doi: 10.1136/bmj.38313.639236.82. PubMed DOI PMC

Paci E, Coviello E, Miccinesi G, Puliti D, Cortesi L, De Lisi V, Ferretti S, Mangone L, Perlangeli V, Ponti A. et al.Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis. Eur J Cancer. 2008;44:858–865. doi: 10.1016/j.ejca.2008.02.026. PubMed DOI

Ascunce EN, Moreno-Iribas C, Barcos Urtiaga A, Ardanaz E, Ederra Sanz M, Castilla J, Egues N. Changes in breast cancer mortality in Navarre (Spain) after introduction of a screening programme. J Med Screen. 2007;14:14–20. doi: 10.1258/096914107780154558. PubMed DOI

SOSSEG. Reduction in breast cancer mortality from the organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev. 2006;15:45–51. PubMed

SOSSEG. Reduction in breast cancer mortality from the organised service screening with mammography: 2. Validation with alternative analytic methods. Cancer Epidemiol Biomarkers Prev. 2006;15:52–56. PubMed

Klabunde C, Bouchard F, Taplin S, Scharpantgen A, Ballard-Barbash R. Quality assurance for screening mammography: an international comparison. J Epidemiol Community Health. 2001;55:204–212. doi: 10.1136/jech.55.3.204. PubMed DOI PMC

Klabunde CN, Sancho-Garnier H, Broeders M, Thoresen S, Rodrigues VJ, Ballard-Barbash R. Quality assurance for screening mammography data collection systems in 22 countries. Int J Technol Assess Health Care. 2001;17:528–541. PubMed

Day NE. Overdiagnosis and breast cancer screening. Breast Cancer Res. 2005;7:228–229. doi: 10.1186/bcr1321. PubMed DOI PMC

Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. Bmj. 2009;339:b2587. doi: 10.1136/bmj.b2587. PubMed DOI PMC

Ascunce N, Salas D, Zubizarreta R, Almazan R, Ibanez J, Ederra M. Cancer screening in Spain. Ann Oncol. 2010;21(Suppl 3):iii43–51. PubMed

Bennett RL, Blanks RG, Patnick J, Moss SM. Results from the UK NHS Breast Screening Programme 2000-05. J Med Screen. 2007;14:200–204. doi: 10.1258/096914107782912068. PubMed DOI

Vejborg I, Olsen AH, Jensen MB, Rank F, Tange UB, Lynge E. Early outcome of mammography screening in Copenhagen 1991-99. J Med Screen. 2002;9:115–119. doi: 10.1136/jms.9.3.115. PubMed DOI

Sarkeala T, Anttila A, Forsman H, Luostarinen T, Saarenmaa I, Hakama M. Process indicators from ten centres in the Finnish breast cancer screening programme from 1991 to 2000. Eur J Cancer. 2004;40:2116–2125. doi: 10.1016/j.ejca.2004.06.017. PubMed DOI

Autier P, Shannoun F, Scharpantgen A, Lux C, Back C, Severi G, Steil S, Hansen-Koenig D. A breast cancer screening programme operating in a liberal health care system: the Luxembourg Mammography Programme, 1992-1997. Int J Cancer. 2002;97:828–832. doi: 10.1002/ijc.10161. PubMed DOI

Oberaigner W, Buchberger W, Frede T, Knapp R, Marth C, Siebert U. Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening. BMC Public Health. p. 86. PubMed PMC

Bihrmann K, Jensen A, Olsen AH, Njor S, Schwartz W, Vejborg I, Lynge E. Performance of systematic and non-systematic ('opportunistic') screening mammography: a comparative study from Denmark. J Med Screen. 2008;15:23–26. doi: 10.1258/jms.2008.007055. PubMed DOI

Bordoni A, Probst-Hensch NM, Mazzucchelli L, Spitale A. Assessment of breast cancer opportunistic screening by clinical-pathological indicators: a population-based study. Br J Cancer. 2009;101:1925–1931. doi: 10.1038/sj.bjc.6605378. PubMed DOI PMC

de Gelder R, Bulliard JL, de Wolf C, Fracheboud J, Draisma G, Schopper D, de Koning HJ. Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. Eur J Cancer. 2009;45:127–138. doi: 10.1016/j.ejca.2008.09.015. PubMed DOI

Bulliard JL, Ducros C, Jemelin C, Arzel B, Fioretta G, Levi F. Effectiveness of organised versus opportunistic mammography screening. Ann Oncol. 2009;20:1199–1202. doi: 10.1093/annonc/mdn770. PubMed DOI

Chamot E, Charvet AI, Perneger TV. Who gets screened, and where: a comparison of organised and opportunistic mammography screening in Geneva, Switzerland. Eur J Cancer. 2007;43:576–584. doi: 10.1016/j.ejca.2006.10.017. PubMed DOI

Jensen A, Olsen AH, von Euler-Chelpin M, Helle Njor S, Vejborg I, Lynge E. Do nonattenders in mammography screening programmes seek mammography elsewhere? Int J Cancer. 2005;113:464–470. doi: 10.1002/ijc.20604. PubMed DOI

Broeders MJ, Scharpantgen A, Ascunce N, Gairard B, Olsen AH, Mantellini P, Mota TC, Van Limbergen E, Seradour B, Ponti A. et al.Comparison of early performance indicators for screening projects within the European Breast Cancer Network: 1989-2000. Eur J Cancer Prev. 2005;14:107–116. doi: 10.1097/00008469-200504000-00006. PubMed DOI

Sahin AA, Guray M, Hunt KK. Identification and biologic significance of micrometastases in axillary lymph nodes in patients with invasive breast cancer. Arch Pathol Lab Med. 2009;133:869–878. PubMed

Madsen AH, Jensen AR, Christiansen P, Garne JP, Cold S, Ewertz M, Overgaard J. Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population based study form the Danish Breast Cancer Cooperative Group. Acta Oncol. 2008;47:239–247. doi: 10.1080/02841860701727436. PubMed DOI

Chen TH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics. 2000;56:167–172. doi: 10.1111/j.0006-341X.2000.00167.x. PubMed DOI

Brett J, Austoker J, Ong G. Do women who undergo further investigation for breast screening suffer adverse psychological consequences? A multi-centre follow-up study comparing different breast screening result groups five months after their last breast screening appointment. J Public Health Med. 1998;20:396–403. PubMed

Lynge E, Olsen AH, Fracheboud J, Patnick J. Reporting of performance indicators of mammography screening in Europe. Eur J Cancer Prev. 2003;12:213–222. doi: 10.1097/00008469-200306000-00008. PubMed DOI

Giordano L, Giorgi D, Piccini P, Stefanini V, Castagno R, Senore C. Time trends of some indicators of mammography screening programmes in Italy, 1996-2003. Epidemiol Prev. 2006;30:17–26. PubMed